SOLICITATION NOTICE
A -- Medication Discovery Using Rat Relapse Models
- Notice Date
- 1/15/2014
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, 6001 Executive Boulevard, Room 4211 - MSC 9559, Bethesda, Maryland, 20892, United States
- ZIP Code
- 20892
- Solicitation Number
- N01DA-14-8917
- Point of Contact
- Jeffrey R Schmidt, Phone: (301) 443-6677, Brian H O'Laughlin, Phone: (301) 443-6677
- E-Mail Address
-
schmidtjr@mail.nih.gov, olaughlinb@mail.nih.gov
(schmidtjr@mail.nih.gov, olaughlinb@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Institute on Drug Abuse plans to solicit proposals from offerors having in-house capability to develop methodologies and to perform in vivo rodent behavioral pharmacology for other drug dependence disorders, using drug self-administration reinstatement models. The objectives of this contract are to determine the in vivo efficacy of novel compounds in animal models of relapse. This includes the following tests in animals trained to self-administer cocaine: (1) the ability of test compound to block footshock or other stress-induced reinstatement of responding after a period of experimental extinction; (2) the ability of a test compound to block cocaine-priming-induced reinstatement of responding after a period of extinction; and (3) the ability of a test compound to block the effects of a conditioned cue (previously paired with cocaine) to reinstate responding for cocaine after a period of extinction. Due to the nature of the compounds which will be evaluated under this contract, it is mandatory that offerors possess a Drug Enforcement Agency (DEA) Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970. In addition, the successful offeror must either possess, or demonstrate the ability to obtain a DEA registration for Schedule I controlled substances. We anticipate the award of one cost reimbursement, severable, level-of-effort contract with a base period of one year with four option years. In addition to the options to extend the contract period of performance, option quantities are also anticipated. RFP No. N01DA-14-8917 will be available electronically on or about February 4, 2014. You can access the RFP through the FedBizOpps (URL: http://fedbizopps.gov) or through the NIDA website: (URL: http://www.drugabuse.gov/funding/funding-opportunities/nida-requests-contract-proposals-rfps). All information required for the submission of a proposal will be contained in or accessible through the RFP package. Responses to the RFP will be due 45 days from the release date. NIDA will consider proposals submitted by any responsible offeror. This advertisement does not commit the Government to award a contract. Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice. Contracting Office Address NIDA R&D Contracts Management Branch 6001 Executive Boulevard Room 4211, MSC 9559 Bethesda, Maryland 20892-9559* *Use Rockville, MD 20852 for Fed-Ex/USPS/Courier/Hand-Delivery
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-01/N01DA-14-8917/listing.html)
- Record
- SN03268121-W 20140117/140115234101-5ac014cee3abae64a58c8bf5c2e21df3 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |